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     The “essential” amino acid tryptophan has a fascinating history. Even its discovery by Gowland Hopkins at 
the beginning of the twentieth century, in accidental observations reputedly stemming from the presence of 
glyoxylic acid contamination in bottles of acetic acid, was quite unusual. The description “essential” is not 
strictly appropriate since large numbers of bacterial cells within the gut synthesise tryptophan which can enter 
the host circulation.  
     In the decades following the discovery of tryptophan it became clear that this amino acid was the primary 
mammalian origin for the synthesis of nicotinic acid and nicotinamide (forms of niacin, vitamin B3) and the co-
factor nicotinamide adenine dinucleotide (NAD), a biochemically versatile compound essential for the 
functioning of many mammalian enzymes. The pathway from tryptophan to nicotinamide became known as the 
kynurenine pathway, named after the first stable compound generated by the oxidation of tryptophan. 
Kynurenine itself, however, appeared to be biologically inactive and, as a result, the pathway between 
tryptophan and nicotinamide held little interest. This attitude persisted until two new chapters were opened in 
the early 1980s. One of these, most directly relevant to the article by Badawy et al. [1] was the observation that 
interferon-ɣ, produced by mammalian cells when exposed to infection or inflammatory conditions, powerfully 
activated the first enzyme of the extra-hepatic kynurenine pathway, indoleamine-2,3-dioxygenase (IDO). This 
activation was associated with a suppression of the proliferation of infecting organisms and, since that 
suppression could be prevented by raising the tryptophan levels (in cell cultures), the mechanism of suppression 
was simplistically attributed to the reduction in tryptophan preventing protein synthesis and cell division [2-4].  
However, this “tryptophan depletion” concept was challenged from its outset by the opposing proposal that the 
further metabolites of tryptophan generated along the kynurenine pathway might be involved in the anti-
infective activity via some form of toxic action on the invading cells, rather than a simple reduction in 
tryptophan levels. 
     It was to take another five years before the same principle of tryptophan depletion was invoked to explain 
one of the most important phenomena in biology. This was the finding that kynurenine pathway activity was 
required for successful implantation, growth and development of an embryo. Inhibiting the first enzyme of the 
pathway, IDO, in pregnant animals (using 1-methyl-tryptophan) led to spontaneous abortion and the loss of 
most embryos [5]. It was suggested that this phenomenon arose from IDO activity in the foetus or placenta 
which normally maintained local tryptophan concentrations at a low level by oxidising it to kynurenine. That 
subnormal level of tryptophan was thought to inhibit the proliferation and activity of maternal immune system T 
cells which form part of the surveillance system that seeks out and destroys foreign cells. By blocking IDO, 
therefore, this T cell suppression could not occur and the T cells could then attack and kill the embryonic cells 
as if they were a foreign (allogeneic) organism. 
    Fascinating though this idea was, it was soon tempered by the increasing acceptance that kynurenine 
metabolites had a range of actions on cells of the immune system, including T cells [6]. Thus, for more than 20 
years there has been an unease in the tryptophan community, especially its kynurenine pathway branch, with a 
lack of clarity and confidence in the mechanistic consequences of IDO activation, an unease compounded by the 
fact that if the kynurenine pathway is a fundamental requirement for  successful reproduction and for anti-
infective immune defences, it is one of the most important pathways in the mammalian body and one which 
should be better understood.  
     It is in this context that the review by Badawy et al. [1] should be viewed. The authors have brought together 
the arguments for and against the tryptophan depletion concept, criticising the former by a series of reasoned 
arguments and reminders that tryptophan regulation is an extremely complex phenomenon in which all the 
components must be considered.  For example, the high affinity but low capacity enzyme IDO does not control 
overall tryptophan metabolism. Firstly, there are at least two isoforms, IDO-1 and IDO-2, which are active in 
different tissues under different conditions. Secondly and more importantly, the largely hepatic enzyme 
tryptophan-2,3-dioxygenase (TDO, also existing in two isoforms) has a much higher capacity and, under 
normal, resting conditions, will be the prime regulator of systemic tryptophan levels, likely to mask any effects 
of IDO in placental, foetal or immune system cells. 
     Another serious argument is that systemic tryptophan levels in vivo could not be lowered enough to starve 
attacking cells without compromising the health of mother or foetus. This might be partially countered by noting 
that local changes in tryptophan concentrations could be generated by locally activated IDO, without the need to 
change circulating levels that affect the whole organism. Activity of IDO is normally low until it is activated by 
interferons and cytokines as part of the inflammatory and anti-infective activity of the immune system, when it 
might be able to control local tryptophan concentrations in the immediate vicinity of susceptible cells. Indeed, 
one might speculate that the ability to regulate systemic tryptophan levels via hepatic TDO  in the face of 
varying food intake or periods of starvation, with IDO serving as a regulator of local tryptophan concentrations 
depending on inflammatory activation, could have contributed to the evolution of these two parallel, but distinct 
enzymes performing similar biochemical functions. Although induction of IDO is obvious with infection, 
however, a clearer view of how it is induced and regulated in the foetus and placenta would be useful. 
Oestrogens can reduce IDO activity in the brain as well as inhibiting TDO in the liver, but there is existing 
evidence that oestrogens activate or up-regulate IDO in the placenta and progestogens down-regulate the 
enzyme. Regional differences such as these would be highly relevant to understanding the overall functional 
role of kynurenines in pregnancy and the overall dynamics of the kynurenine pathway in pregnancy merit more 
detailed analysis at the cellular and biochemical levels.  
     But if the depletion hypothesis is no longer tenable, is the concept that increased formation of kynurenine 
metabolites  - the “tryptophan utilisation” hypothesis championed by Badawy et al.[1] – a viable alternative 
explanation for the local control of immune system activity?  A major difficulty often raised with this hypothesis 
is that raised tryptophan levels oppose the cell suppressant effect of IDO activation. If IDO activity works by 
reducing local tryptophan concentrations, this makes sense viewed as a simple restoration of normal tryptophan 
availability. However, if IDO activation suppresses cell viability by increasing the formation of kynurenine 
metabolites, then that activity should be potentiated by supplying higher amounts of tryptophan.  Badawy et al. 
[1] try to resolve this issue by reminding us that excessive amounts of tryptophan, over around 200μM, can 
inhibit IDO. Thus, high local concentrations of tryptophan should not be expected simply to counteract the 
effects of local depletion. Such an explanation would certainly help understanding of these inter-relationships, 
but it is one which also requires more intensive analysis and understanding of the kinetic interactions between 
all the enzymes and metabolites in the kynurenine pathway 
     It is valuable to be reminded by Badawy et al. [1] of problems in the experimental design or tools used in 
previous work on tryptophan biology. One problem is undoubtedly the failure to consider the roles of bound and 
free tryptophan. Most studies measure total plasma levels, but these can vary independently of local 
concentrations. Indeed bound tryptophan will act as a buffer reservoir in most situations, combatting any 
tendency for tryptophan levels to fall. Total plasma levels are known to fall during pregnancy as a result of 
increased uptake into cells which is probably necessary to maintain healthy cells in the mother in parallel with 
intense new growth activity in the foetus. Yet free tryptophan levels are increased in pregnancy, a phenomenon 
which would not fit with the depletion hypothesis of T cell suppression.  
     Equally, in experimental conditions where more direct interference with enzyme activity is possible, tools 
that are sufficiently selective have not been available until recently. One of the key compounds used to block 
IDO activity and thus inhibit the kynurenine pathway was 1-methyl-tryptophan, but it is now recognised that 
this compound also inhibits tryptophan transport and up-regulates IDO expression. The latter, of course, might 
be secondary to the former, but interpretation remains difficult and more detailed work is required. There remain 
questions about the interactions between kynurenine metabolites that might complicate interference with 
tryptophan availability. For example it is clear that inflammation is associated with a change in the balance 
between 3-hydroxy-anthranilic acid and anthranilic acid concentrations [7]. The ratio between these compounds 
seems to correlate with inflammatory activity and anthranilic acid is the structural basis of many recognised and 
experimental anti-inflammatory drugs. How does this fit with the actions of these compounds on the immune 
system and their relative amounts in the face of changes in IDO activity and tryptophan availability? 
     Why is all this important? Three reasons. Firstly, the same self-protection generated by IDO activity in the 
foetus and placenta also applies to many cancer cells. IDO expression is high in these cells, resulting in T cell 
suppression and cancer cell escape from detection and destruction. Producing inhibitors of IDO has become big 
business, with most pharmaceutical companies generating them to block IDO in cancer cells, thus reducing their 
resistance to immune attack and increasing their susceptibility to traditional chemotherapeutic agents. Given the 
doses and long periods for which anti-cancer drugs are often required, it is important to understand fully how 
these compounds work and what other long-term effects might be produced or influenced by kynurenine 
metabolites. 
     Secondly, there is a growing interest in the overlap between kynurenines in the immune system and their 
effects on the nervous system. The other new chapter on the kynurenine pathway in the 1980s actually began 
two years before Pfefferkorn’s paper [4], with the discovery that one component of the pathway – quinolinic 
acid, the precursor of nicotinic acid – excited neurons in the cerebral cortex by acting on glutamate receptors 
sensitive to N-methyl-D-aspartate (NMDA) [8] and were becoming a focus of attention as they possessed 
unique properties of fundamental importance in a range of cerebral phenomena. These included synaptic 
plasticity (implying a role in learning and memory processes and all the cognitive functions based on these), 
cyclical depolarising shifts (which implied a possible role in abnormal excitability states such as epilepsy), and 
the promotion of calcium influx (which implied relevance for excitotoxicity and neurodegenerative disorders 
such as Alzheimer's disease, Huntington’s disease and strokes) [8]. Even more intriguing was the subsequent 
discovery that another metabolite of kynurenine – kynurenic acid – was an antagonist at these same NMDA-
sensitive receptors, leading to the concept that the balance of concentrations of quinolinic acid and kynurenic 
acid could be of fundamental importance in normal and abnormal brain function [8]. By regulating both immune 
system activity and the excitability and synaptic function in the nervous system, tryptophan has therefore 
become a key player in the integration of these systems. Changes in the immune system will alter kynurenine 
pathway activity and, secondarily, brain function. Conversely, neuronal and the associated glial cell activity in 
the brain, will alter kynurenine pathway activity which could affect immune cell function peripherally. Is this 
why we have difficulty thinking and focussing when we have an infection or significant inflammation 
peripherally?  Is it why the activity of our immune system – and thus our sensitivity to infections and cancer – 
depends on our state of mental activity, mood and outlook?  Is this how psychological treatments, faith healing 
and placebos work their magic? The kynurenine pathway may be the key to a new era of understanding and the 
design of integrated, holistic approaches to health and medicine.  
     Thirdly, raising these many problems and discrepant interpretations should encourage a more detailed and 
systematic analysis of the inter-relationships between the components of tryptophan metabolism. An outstanding 
example of this is the need integrate the finding that IDO has non-enzymic functions in the regulation of 
immune dendritic cells [9]. This, and perhaps other unidentified features of tryptophan metabolism serve to 
emphasise how multi-faceted and fundamental this pathway is in mammalian biology. 
     Lastly, in writing their review, Badawy and colleagues [1] also correct some accumulated, historical errors of 
citation. Sometimes claims to the importance of earlier work reveal incidental observations that would have had 
no meaning in themselves until they were placed into an explanatory, functional, biologically meaningful 
context by later work, so that the earlier citations are not appropriate. In the case of IDO, however, the first 
indication of its induction by infection  [2,3] has long been overlooked and, as proposed by Badawy et al. [1], 
ought to receive the credit due.  
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